MarketPR
TCW Funds initiated a position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the second quarter of 2026, a move detailed in the firm's latest investor letter for the TCW Relative Value Mid Cap Fund.
The biotechnology company, headquartered in San Rafael, California, closed at $60.00 on September 30, 2026, reflecting a market capitalization of $11.61 billion at that date.
TCW noted that BioMarin met three of five valuation characteristics at the time of initiation, specifically regarding its price-to-earnings, price-to-cash flow, and price-to-book ratios.
The investment firm reported that the fund returned 14.10% in the quarter, outperforming the S&P 500's 13.40% gain.
Keep reading